Drug Trial Radar · NCT06554795
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Sep 3, 2024
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Conditions
- Solid Tumor, Adult
Interventions
DB-1419Drug
Administered Injection of Vein (I.V.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1/2a: Percentage of Participants with Adverse events (AE) serious AE (SAE)Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first
- Phase 1/2a: Percentage of Participants with serious AE (SAE)Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first
- Phase 1a: Maximum Tolerated Dose (MTD)Time frame: From first study treatment administration until the initiation of Phase1b/2a, approximately up to 12 months.
- Phase 1a: Recommended Phase 2 Dose (RP2D)Time frame: From first study treatment administration until the initiation of Phase 1b/2a, approximately up to 12 months.
- Phase 1b/2a: Objective Response Rate (ORR) determined by Investigator per RECIST v1.1Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.
Locations
36 sites in 3 countries. Site status is shown where the registry gives one.
Site USA12-0
Los Angeles, California · Recruiting
Site USA08-0
Newport Beach, California · Recruiting
Site USA06-0
Washington D.C., District of Columbia · Recruiting
Site USA02-0
Florida City, Florida · Recruiting
Site USA11-0
Chicago, Illinois · Recruiting
Site USA03
Huntersville, North Carolina · Recruiting
Site USA05-0
Philadelphia, Pennsylvania · Not yet recruiting
Site USA07-0
Nashville, Tennessee · Recruiting
Site USA09-0
West Valley City, Utah · Recruiting
AUS03-0
North Ryde, New South Wales, Australia · Recruiting
AUS01-0
Randwick, New South Wales, Australia · Recruiting
AUS02-0
Nedlands, Washington, Australia · Recruiting
Site CHN24-0
Hefei, Anhui, China · Not yet recruiting
Site CHN39-0
Hefei, Anhui, China · Not yet recruiting
Site CHN28-0
Beijing, Beijing Municipality, China · Not yet recruiting
Site CHN13-0
Jilin City, Changchun, China · Not yet recruiting
Site CHN16-0
Chongqing, Chongqing Municipality, China · Recruiting
Site CHN20-0
Fuzhou, Fujian, China · Recruiting
Site CHN32-0
Nanning, Guangxi, China · Not yet recruiting
Site CHN08-0
Harbin, Heilongjiang, China · Recruiting
Site CHN23-0
Harbin, Heilongjiang, China · Not yet recruiting
Site CHN03-0
Luoyang, Henan, China · Recruiting
Site CHN09-0
Zhengzhou, Henan, China · Not yet recruiting
Site CHN25-0
Zhengzhou, Henan, China · Not yet recruiting
Site CHN34-0
Wuhan, Hubei, China · Recruiting
Site CHN21-0
Changsha, Hunan, China · Recruiting
Site CHN31-0
Shenyang, Liaoning, China · Not yet recruiting
Site CHN29-0
Jinan, Shandong, China · Not yet recruiting
Site CHN26-0
Linyi, Shandong, China · Recruiting
Site CHN01-0
Shanghai, Shanghai Municipality, China · Recruiting
Site CHN15-0
Shanghai, Shanghai Municipality, China · Recruiting
Site CHN18-0
Chengdu, Sichuan, China · Recruiting
Site CHN38-0
Tianjin, Tianjin Municipality, China · Not yet recruiting
Site CHN19-0
Kunming, Yunnan, China · Not yet recruiting
Site CHN17-0
Hangzhou, Zhejiang, China · Not yet recruiting
Site CHN37-0
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.